Ann Rheum Dis

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rau, R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rau, R
Annals of the Rheumatic Diseases 2002;61:ii70-ii73
© 2002 by Annals of the Rheumatic Diseases


REPORT

Adalimumab (a fully human anti-tumour necrosis factor {alpha} monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials

R Rau

Department of Rheumatology, Evangelisches Fachkrankenhaus Ratingen, Ratingen, Germany

Correspondence to:
Correspondence to:
Dr R Rau, Rheumaklinik, Evangelisches Fachkrankenhaus, Rosenstr 2 D-40882 Ratingen, Germany;
rrau@uni-duesseldorf.de

Keywords: rheumatoid arthritis; adalimumab

Abbreviations: RA, rheumatoid arthritis; TNF{alpha}, tumour necrosis factor {alpha}; MTX, methotrexate; DMARD, disease modifying antirheumatic drug

The first 150 words of the full text of this article appear below.

Rheumatoid arthritis (RA), a common, chronic, idiopathic autoimmune disease, is characterised by symmetrical synovitis, inflammatory exudates in the joint cavity, and erosion of articular cartilage and marginal bone.1 Standard treatment for RA typically consists of traditional disease modifying antirheumatic drugs (DMARDs), corticosteroids, non-steroidal anti-inflammatory drugs, and analgesics.2 Despite these various treatments, many patients with RA continue to experience substantial disease activity, with progressive joint damage and accompanying functional loss. In recent years, insights into the pathophysiology of RA have lead to the development of novel therapeutic strategies that target underlying disease processes, the most promising of which entails neutralisation of tumour necrosis factor {alpha} (TNF{alpha}).3


ANTI-TNF{alpha} TREATMENTS
TNF{alpha} is a potent proinflammatory cytokine that plays a critical part in the progression of inflammatory synovitis and articular matrix degradation in RA.3 Increased concentrations of TNF{alpha} are found in the synovial fluid and serum of patients with active RA.4 Derived primarily from activated monocytes . . . [Full text of this article]




This article has been cited by other articles:


Home page
Br. J. Ophthalmol.Home page
S. Biester, C. Deuter, H. Michels, R. Haefner, J. Kuemmerle-Deschner, D. Doycheva, and M. Zierhut
Adalimumab in the therapy of uveitis in childhood
Br. J. Ophthalmol., March 1, 2007; 91(3): 319 - 324.
[Abstract] [Full Text] [PDF]


Home page
Protein Eng Des SelHome page
Z. L. Fredericks, C. Forte, I. V. Capuano, H. Zhou, T. Vanden Bos, and P. Carter
Identification of potent human anti-IL-1RI antagonist antibodies
Protein Eng. Des. Sel., January 1, 2004; 17(1): 95 - 106.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
M C Hochberg, J K Tracy, M Hawkins-Holt, and R H Flores
Comparison of the efficacy of the tumour necrosis factor {alpha} blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis
Ann Rheum Dis, November 1, 2003; 62(90002): ii13 - 16.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2002 BMJ Publishing Group Ltd & European League Against Rheumatism